Pharmaceutical heavy metal analysis: securing your batches for ICH Q3D

In the pharmaceutical industry, the presence of heavy metals and elemental impurities can jeopardize batch release, delay a regulatory submission, or trigger a quality nonconformity. The challenge is not only analytical: it also involves controlling raw materials, excipients, active pharmaceutical ingredients, process water, packaging components, and finished products. A pharmaceutical analysis approach aligned with the expectations of ICH Q3D makes it possible to identify the elements to monitor, verify their content, and document the compliance of your products. Commonly targeted elements include arsenic, cadmium, mercury, and lead, as well as nickel, cobalt, vanadium, antimony, copper, chromium, and molybdenum. To explore instrumental approaches suited to the sector, see our Pharmaceutical ICP Analysis page.

ICH Q3D structures the assessment of elemental impurities by class. Class 1 elements include arsenic, cadmium, mercury, and lead. Class 2 elements include cobalt, nickel, and vanadium. Class 2B groups elements such as silver, gold, thallium, palladium, platinum, iridium, osmium, rhodium, ruthenium, and selenium. Class 3 may concern antimony, barium, lithium, chromium, copper, tin, and molybdenum. The selection of analytes depends on the risk assessment, the materials used, and the manufacturing process.

The determination of elemental impurities relies on reference techniques such as ICP-MS, ICP-MS/MS, and ICP-AES. These tools make it possible to quantify metallic traces in pharmaceutical matrices with quantification limits that can go down to 0.1 ppm depending on the element and the matrix. ICP-MS/MS is particularly useful when spectral interferences must be controlled. ICP-AES may be selected for certain assays when the expected levels and the matrix allow it. For mercury, a cold vapor analyzer may also be used depending on the analytical need.

An expert laboratory brings more than just a numerical result. It helps build the control strategy, choose the most relevant technique, interpret the data, and document compliance within a demanding regulatory framework. Support can include method development, analytical validation according to USP 233 or ICH Q2, as well as training on the requirements of ICH Q3D. This approach is particularly useful during an analytical transfer, a risk review, an OOS investigation, or a formulation change.

An expert laboratory supports pharmaceutical manufacturers in method development, quantification of the 24 elemental impurities covered by ICH Q3D, and analytical validation according to the applicable references, including USP 233 and ICH Q2. This expertise covers investigations on raw materials, intermediates, gels, finished dosage forms, and complex matrices. It makes it possible to adapt the analytical strategy to the product, the matrix, the expected sensitivity level, and the client’s quality objectives. Support can also include R&D assistance, nonconformity investigations, assessment of contamination from processes or packaging, as well as the development of tailor-made methods for routine or validation needs.

The control plan must be sized according to the nature of the product: active ingredient, excipient, semi-solid form, solution, gel, or finished product. It may also include investigations on process water, cleaning residues, packaging, or contact materials. For related residual contamination issues, you can also consult our expertise on Residus Metaux Lourds Iso 19227.

The quality of the result depends heavily on sample preparation. Microwave digestion can be implemented to solubilize the matrix and ensure robust measurement. This step is essential for finished products, gels, complex formulations, or materials likely to introduce contaminants. Depending on the case, the laboratory can also address related issues involving particles or material contamination, for example via the page Unknown Particles in Pharmaceutical Products.

Using an ISO 17025 accredited laboratory by COFRAC for pharmaceutical and cosmetic activities is an asset for making your analytical data more reliable. This setup can meet routine needs as well as specific requests: failure investigation, trace analysis of catalysts, packaging material assessment, or support for optimizing industrial processes. In some cases, complementary expertise on materials and formulations may also be relevant, such as our Polymer Rheology Analysis Laboratory for the Pharmaceutical Industry.

To start a service, it is necessary to specify the nature of the matrix, the target elements, the regulatory context, the expected thresholds, and the final need: release testing, risk assessment, method development, validation, or investigation. The laboratory can then propose a suitable analytical strategy, carry out the tests, and deliver actionable results for your quality, control, or regulatory affairs teams. To move forward efficiently: define the analytical scope, submit product and process information, analyze the samples with the appropriate technique, validate the method if necessary, document the compliance of your batches.